The last time I wrote an article on Alkermes (ALKS) it was with respect to a Seeking Alpha article entitled "Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage". In this article ...
Sarepta Therapeutics' gene therapy Elevidys has been granted label extension to treat Duchenne Muscular Dystrophy patients aged 4 and above. Sarepta Therapeutics stock price soars over 30% to >$160 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback